2-methylthio-(E,E)-4,6-bis-(3'-hydroxy-4'-methoxystyryl)pyrimidine | 1236355-47-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: 2-methylthio-(E,E)-4,6-bis-(3'-hydroxy-4'-methoxystyryl)pyrimidine
• 英文别名: 5-[(E)-2-[6-[(E)-2-(3-hydroxy-4-methoxyphenyl)ethenyl]-2-methylsulfanylpyrimidin-4-yl]ethenyl]-2-methoxyphenol
• CAS: 1236355-47-7
• 化学式: C₂₃H₂₂N₂O₄S
• 分子量: 422.505
• InChiKey: ZMWKKMYINWOOSX-KBXRYBNXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-methylthio-(E,E)-4,6-bis[4'-methoxy-3'-(4''-methoxybenzyloxy)styryl]pyrimidine 在 盐酸 作用下， 以 乙醇 、 水 为溶剂， 以30%的产率得到2-methylthio-(E,E)-4,6-bis-(3'-hydroxy-4'-methoxystyryl)pyrimidine
  参考文献：
  名称：

  Small molecules that protect against β-amyloid-induced cytotoxicity by inhibiting aggregation of β-amyloid

  摘要：

  Aggregated beta-amyloid (A beta) plays crucial roles in Alzheimer's disease (AD) pathogenesis, therefore blockade of Ab aggregation is considered as a potential therapeutic target. We designed and synthesized small molecules to reduce A beta-induced cytotoxicity by inhibiting A beta aggregation. The small molecules were screened via ThT, MTT, and cell-based cytotoxicity assay (A beta burden assay). Selected compounds 1c, 1d, 1e, and 1f were then investigated by evaluating their effects on cognitive impairment of acute AD mice model. Learning and memory dysfunction by injection of A beta(1-42) was recovered by administration of these molecules. Especially, 1d showed the best recovery activity in Y-maze task, object recognition task, and passive avoidance task with dose dependent manner. These results suggest that 1d has high potential as a therapeutic agent for AD. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.06.045

文献信息

• BIS(STYRYL)PYRIMIDINE OR BIS(STYRYL)BENZENE COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASES FEATURING AMYLOIDS COMPRISING THE SAME AS AN ACTIVE INGREDIENT
  申请人：SHIN Kye Jung

  公开号：US20100190803A1

  公开（公告）日：2010-07-29

  Disclosed are bis(styryl)pyrimidine or bis(styryl)benzene compounds, represented by Chemical Formula 1, pharmaceutically acceptable salts, a method for preparing the same, and a pharmaceutical composition for the prevention and treatment of amyloidosis-associated diseases, comprising the same as an active ingredient. Having the ability to inhibit the deposition of beta amyloid and to reduce the toxicity of beta amyloid, the derivatives can improve learning and memory and can be useful in the prevention and treatment of amyloidosis-associated diseases. (wherein R 1 , R 2 , R 3 and X are as defined in the specification)

  本发明涉及一种由化学式1表示的双(苯乙烯基)嘧啶或双(苯乙烯基)苯化合物，其药学上可接受的盐，其制备方法以及一种药物组合物，用于预防和治疗与淀粉样蛋白病相关的疾病，其中该化合物为活性成分。该衍生物具有抑制β淀粉样蛋白沉积和减少其毒性的能力，可以改善学习和记忆，并且可以在预防和治疗与淀粉样蛋白病相关的疾病方面有用。（其中R1、R2、R3和X如规范中所定义）
• US8410116B2
  申请人：——

  公开号：US8410116B2

  公开（公告）日：2013-04-02
• Small molecules that protect against β-amyloid-induced cytotoxicity by inhibiting aggregation of β-amyloid
  作者：Yun Suk Lee、Hye Yun Kim、YoungSoo Kim、Jae Hong Seo、Eun Joo Roh、Hogyu Han、Kye Jung Shin

  DOI：10.1016/j.bmc.2012.06.045

  日期：2012.8

  Aggregated beta-amyloid (A beta) plays crucial roles in Alzheimer's disease (AD) pathogenesis, therefore blockade of Ab aggregation is considered as a potential therapeutic target. We designed and synthesized small molecules to reduce A beta-induced cytotoxicity by inhibiting A beta aggregation. The small molecules were screened via ThT, MTT, and cell-based cytotoxicity assay (A beta burden assay). Selected compounds 1c, 1d, 1e, and 1f were then investigated by evaluating their effects on cognitive impairment of acute AD mice model. Learning and memory dysfunction by injection of A beta(1-42) was recovered by administration of these molecules. Especially, 1d showed the best recovery activity in Y-maze task, object recognition task, and passive avoidance task with dose dependent manner. These results suggest that 1d has high potential as a therapeutic agent for AD. (C) 2012 Elsevier Ltd. All rights reserved.